PFG Investments LLC Purchases New Position in Vaxart, Inc. (NASDAQ:VXRT)

PFG Investments LLC acquired a new stake in Vaxart, Inc. (NASDAQ:VXRT) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,450 shares of the biotechnology company’s stock, valued at approximately $38,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Beacon Capital Management LLC raised its holdings in shares of Vaxart by 369.9% during the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 40,000 shares during the period. Kingswood Wealth Advisors LLC acquired a new position in shares of Vaxart during the first quarter worth $32,000. Finally, AE Wealth Management LLC boosted its stake in shares of Vaxart by 180.7% in the third quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 39,987 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, B. Riley raised shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Wednesday, January 31st.

Vaxart Trading Down 2.7 %

NASDAQ VXRT traded down $0.02 during mid-day trading on Friday, reaching $0.73. 2,158,370 shares of the company’s stock traded hands, compared to its average volume of 1,458,625. Vaxart, Inc. has a 1-year low of $0.53 and a 1-year high of $1.59. The company has a fifty day simple moving average of $1.05 and a 200-day simple moving average of $0.88. The company has a market cap of $128.90 million, a price-to-earnings ratio of -1.26 and a beta of 0.72.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $3.25 million during the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. Equities research analysts forecast that Vaxart, Inc. will post -0.45 earnings per share for the current fiscal year.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.